Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis
BackgroundSemaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise in managing hyperglycemia and reducing cardiovascular (CV) outcomes. However, its effects on arrhythmic, major CV, and microvascular outcomes remain uncertain. This systematic review and meta-analysis aimed...
Saved in:
| Main Authors: | Rui Wu, Bo Xing, Yuting Huang, Zijun Zhou, Boxuan Sun, Liming Yu, Huishan Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1554795/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Beyond the Beat: Understanding Inherited Risk and Therapeutic Opportunities in Cardiovascular Diseases with Emphasis on Inherited Cardiomyopathies and Inherited Arrhythmic Syndromes
by: Antea Krsek, et al.
Published: (2024-09-01) -
ARRHYTHMIC PHENOTYPE OF NON-COMPACTION CARDIOMYOPATHY
by: S. M. Komissarova, et al.
Published: (2021-05-01) -
Arrhythmic Risk Stratification in Patients with Arrhythmogenic Cardiomyopathy
by: Marisa Varrenti, et al.
Published: (2025-04-01) -
INCREASE IN QTC DISPERSION PREDICTS ARRHYTHMIC EVENTS IN PATIENTS WITH CARDIAC RESYNCHRONIZATION THERAPY
by: Cuneyt Kocas, et al.
Published: (2014-04-01) -
Etomidate Shows Prospect as an Anti-Arrhythmic Drug Conferring Safe Sedation and Sinus Conversion Simultaneously
by: Maryam Saif Al Ali, et al.
Published: (2020-10-01)